Appili Therapeutics
Appili Therapeutics is a Canadian biopharmaceutical company developing anti-infective drugs, including an FDA-approved taste-masked metronidazole oral suspension (LIKMEZ) and a pipeline of biodefense and tropical-disease vaccines funded largely by U.S. government agencies and out-licensed for commercialization.
- Company typePublic
- Founded2015
- HeadquartersHalifax, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Appili Therapeutics does
Appili Therapeutics is a Canadian biopharmaceutical company (TSX: APLI; OTCPink: APLIF) founded in 2015 and headquartered in Halifax, Nova Scotia, with a U.S. office in Frederick, Maryland. The company focuses exclusively on anti-infective drug development across three program categories: a commercial product (LIKMEZ/ATI-1501, an FDA-approved taste-masked metronidazole oral suspension commercialized via partner Saptalis Pharmaceuticals), government-funded biodefense vaccines (ATI-1701 live-attenuated tularemia vaccine under FDA Animal Rule; VXV-01 dual-antigen antifungal vaccine), and a tropical-disease asset (ATI-1801 topical paromomycin for cutaneous leishmaniasis). The portfolio is protected by issued patents (LIKMEZ coverage through 2039), FDA Orphan Drug Designation (ATI-1801), and potential Priority Review Voucher eligibility for ATI-1701 and ATI-1801.
Appili's business model is a hybrid of non-dilutive government contracting and licensed commercialization. The company secures substantial government funding from U.S. agencies — approximately US$14 million from USAFA/DTRA for ATI-1701 and up to US$40 million from NIAID for VXV-01 — to advance its vaccine pipeline without equity dilution. Commercial revenue derives from milestone payments and royalties paid by Saptalis Pharmaceuticals, which holds licensed rights to LIKMEZ across the U.S., Europe, and Latin America. Customer segments are concentrated in two groups: U.S. government agencies funding biodefense and medical countermeasure development, and the single commercialization partner for the only approved product.
The company operates with a small team (11–50 employees) and has reported recurring net losses (approximately US$3.8–4.2 million in recent fiscal years), with capital supplemented by bridge loans (Bloom Burton & Co.) and modest non-brokered private placements. A proposed acquisition by Aditxt Inc. that received 99.79% shareholder approval and court sanction was formally terminated in May 2025, and Appili continues operating as an independent public entity with a market capitalization of approximately C$1.88 million as of February 2026.
Appili Therapeutics firmographics
Firmographics- Name
- Appili Therapeutics
- Legal name
- Appili Therapeutics Inc.
- Website
- https://appilitherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Appili Therapeutics is a Canadian biopharmaceutical company developing anti-infective drugs, including an FDA-approved taste-masked metronidazole oral suspension (LIKMEZ) and a pipeline of biodefense and tropical-disease vaccines funded largely by U.S. government agencies and out-licensed for commercialization.
- Ownership category
- akta.pro rank
Appili Therapeutics industry classification
Industry- Product category
- Anti-infective Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Appili Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Halifax
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Appili Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Product Licensing and Royalties: Appili earns milestone payments and royalties from commercialization partner Saptalis Pharmaceuticals for LIKMEZ sales in the U.S. and other territories. Patent coverage extends through 2039.
- Government Non-Dilutive Funding: The company secures significant government funding for vaccine development programs including US$14 million from USAFA/DTRA for ATI-1701 and US$40 million NIAID contract for VXV-01 fungal vaccine, supporting development through regulatory submissions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Appili Therapeutics product offering
Product offeringCore offering
Appili Therapeutics is a publicly traded anti-infective biopharmaceutical company that develops and reformulates therapeutics and vaccines for unmet needs in infectious disease and biodefense. Its commercial-stage product, LIKMEZ (ATI-1501), is an FDA-approved taste-masked oral suspension of metronidazole for the treatment of anaerobic bacterial and parasitic infections. The pipeline includes ATI-1701, a live-attenuated tularemia vaccine candidate supported by U.S. biodefense funding, ATI-1801, a topical paromomycin for cutaneous leishmaniasis, VXV-01, a fungal vaccine candidate, and ATI-2307, an investigational antifungal.
Product overview
Appili Therapeutics is an infectious disease biopharmaceutical company with a portfolio of anti-infective products. The company has one FDA-approved commercial product (LIKMEZ/ATI-1501, a taste-masked metronidazole oral suspension) and multiple pipeline candidates including ATI-1701 (biodefense vaccine for tularemia), ATI-1801 (topical paromomycin for cutaneous leishmaniasis), VXV-01 (fungal vaccine), and ATI-2307 (antifungal). Products target infectious diseases, biothreat pathogens, and unmet medical needs in antimicrobial treatments.
Differentiator
Problem solved
Functional benefit
Brands
- LIKMEZ: FDA-approved taste-masked liquid oral suspension of metronidazole for treating serious anaerobic and protozoal infections. Trademark of Saptalis Pharmaceuticals, LLC.
Products and services
- LIKMEZ (ATI-1501) FDA-approved taste-masked liquid formulation of metronidazole for the treatment of anaerobic bacterial and parasitic infections in patients who have difficulty swallowing tablets; commercialized through Saptalis Pharmaceuticals.
- ATI-1701 Live-attenuated tularemia vaccine candidate designed as a biodefense countermeasure for the U.S. government against Francisella tularensis, the causative agent of tularemia.
- ATI-1801 Topical paromomycin reformulation for the treatment of cutaneous leishmaniasis, an orphan indication; received FDA Orphan Drug Designation.
- VXV-01 Dual-antigen fungal vaccine candidate targeting Coccidioides (Valley Fever), being developed as a non-dilutive-funded pipeline asset.
- ATI-2307 Investigational antifungal small molecule in early-stage development for difficult-to-treat fungal infections.
Quantifiable outcome
- LIKMEZ achieved FDA approval September 2023, launched commercially November 2023
- +3 more outcomes
Companies that use Appili Therapeutics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Appili Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Appili Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Vitalex BiosciencescoreSubcontractor for US$40 million NIAID contract to develop VXV-01 fungal vaccine. Appili holds exclusive option to acquire worldwide rights to VXV-01. Partnership advances dual-antigen vaccine targeting drug-resistant Candida species through Phase 1 trials.
- Saptalis Pharmaceuticals LLCcoreLicensed commercial rights to LIKMEZ (ATI-1501) for U.S., Europe, and Latin America markets. Saptalis is responsible for manufacturing, FDA-approved formulation using Appili's taste-masking technology, and commercialization. Appili receives milestone payments and royalties on sales.
- FUJIFILMminorAgreement and funding support for clinical trial evaluating Avigan/Reeqonus for COVID-19 patients, expediting completion of Phase 3 study of the oral antiviral medicine.
- U.S. Army Medical Materiel Development Activity (USAMMDA)coreLicensed full clinical dossier for ATI-1801 from USAMMDA, including results from randomized, double-blind, vehicle-controlled Phase 3 study in Tunisia demonstrating safety and efficacy for cutaneous leishmaniasis treatment.
Scale indicators10 records
Recent moves7 records
Expansion highlights5 records
Appili Therapeutics competitors and assessment
Company assessmentDirect peers
- Soligenix: Small-cap biopharmaceutical company with both biodefense (ricin vaccine, thermo-stable technology) and specialty infectious disease programs. Closest size, structure, and pipeline composition peer to Appili.
- Paratek Pharmaceuticals: Anti-infective specialty pharma (Nuzyra/omadacycline) targeting resistant bacterial infections — comparable specialty anti-infective commercial model and government contracting approach to Appili.
- Nabriva Therapeutics: Small anti-infective specialty pharma focused on pleuromutilin antibiotics for community-acquired pneumonia. Similar specialty anti-infective positioning, public small-cap status, and commercial-stage dynamics.
- Iterum Therapeutics: Small-cap anti-infective biotech developing oral sulopenem for resistant infections. Comparable size, public micro-cap status, and anti-infective focus area to Appili.
- Bavarian Nordic: Develops live-attenuated biodefense vaccines including Jynneos (smallpox/mpox) and Ebola vaccine — directly comparable vaccine platform and government stockpile customer profile to Appili's ATI-1701 and VXV-01.
- BioCryst Pharmaceuticals: Anti-infective specialty pharma developing antivirals (influenza, COVID) and antifungals — directly comparable therapeutic focus area to Appili's LIKMEZ, ATI-2307, and VXV-01 programs.
- SIGA Technologies: Small-cap biodefense specialty pharma with Tpoxx (oral tecovirimat) for smallpox — the closest pure-play biodefense antiviral comparable to Appili's ATI-1701 tularemia program. Similar revenue scale and government contracting profile.
Broad incumbents
- Emergent BioSolutions: Largest pure-play biodefense company (anthrax vaccines, smallpox, NARCAN) selling into the same US government stockpiling channels Appili targets with ATI-1701. Larger and more diversified but overlapping customer set.
- Dr. Reddy's Laboratories: Large generic pharmaceutical manufacturer producing generic metronidazole formulations that compete directly with LIKMEZ. Relevant commercial competitor and benchmark for Appili's taste-masked liquid product positioning.
Emerging players
- Tonix Pharmaceuticals: Clinical-stage biopharma with infectious disease vaccine programs (including biodefense candidates) and central nervous system portfolio. Comparable small-cap public status and partial overlap in biodefense vaccine development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Appili Therapeutics social profiles
Digital presenceAppili Therapeutics compliance and trust
Trust signalCompliance2 records
Appili Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Appili Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Appili Therapeutics funding detail
Funding detailFunding overview
Funding rounds18 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Appili Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Appili Therapeutics
What does Appili Therapeutics do?
Appili Therapeutics is a publicly traded anti-infective biopharmaceutical company that develops and reformulates therapeutics and vaccines for unmet needs in infectious disease and biodefense. Its commercial-stage product, LIKMEZ (ATI-1501), is an FDA-approved taste-masked oral suspension of metronidazole for the treatment of anaerobic bacterial and parasitic infections. The pipeline includes ATI-1701, a live-attenuated tularemia vaccine candidate supported by U.S. biodefense funding, ATI-1801, a topical paromomycin for cutaneous leishmaniasis, VXV-01, a fungal vaccine candidate, and ATI-2307, an investigational antifungal.
Is Appili Therapeutics a public or private company?
Appili Therapeutics is a public company. It is classified as public and is currently operating.
When was Appili Therapeutics founded?
Appili Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is Appili Therapeutics based?
Appili Therapeutics is headquartered in Halifax, Canada, in the North America region.
How does Appili Therapeutics make money?
Two revenue lines are on record. Product Licensing and Royalties are the primary driver. The others are government Non-Dilutive Funding.
Who are Appili Therapeutics's main competitors?
Direct peers on record are Soligenix, Paratek Pharmaceuticals, Nabriva Therapeutics, Iterum Therapeutics, Bavarian Nordic, BioCryst Pharmaceuticals and SIGA Technologies. Broad incumbents are Emergent BioSolutions and Dr. Reddy's Laboratories. Tonix Pharmaceuticals is listed as an emerging player.
Does Appili Therapeutics have an API?
No public API is recorded for Appili Therapeutics.
What industry is Appili Therapeutics in?
Appili Therapeutics's product category is Anti-infective Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.